American Journal of Cardiovascular Drugs

, Volume 5, Issue 4, pp 225–231 | Cite as

Therapeutic Potential of Monteplase in Acute Myocardial Infarction

  • Teruo Inoue
  • Ryoichi Nishiki
  • Manabu Kageyama
  • Koichi Node
Leading Article


Thrombolysis with conventional thrombolytic agents prior to percutaneous coronary intervention (PCI) has had no impact on the treatment of acute myocardial infarction (AMI). However, the development of mutant tissue type plasminogen activators (mt-PA) has prompted us to reassess the combination of thrombolysis and PCI. Monteplase is a newly developed mt-PA that can be administered as a single intravenous bolus injection. The results of the COMA (COmbining Monteplase with Angioplasty) trial, suggest that monteplase administration prior to emergent PCI in AMI improves 6-month outcomes and possibly the long-term prognosis of myocardial infarction. Combining monteplase administration on presentation at a community hospital with prompt transfer to a tertiary center for PCI would be an ideal strategy for the treatment of AMI.


  1. 1.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin or both or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988 Aug 13; II(8607): 349–60.Google Scholar
  2. 2.
    White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987 Oct 1; 317(14): 850–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Gruppo Italiano per lo Studio delia Streptochinasi nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986 Feb 22; I(8478): 397–402.Google Scholar
  4. 4.
    The TIMI Research Group. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction: TIMI II A results. JAMA 1988 Nov 18; 260(19): 2849–58.CrossRefGoogle Scholar
  5. 5.
    Simoons ML, Arnold AE, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988 Jan 30; I(8579): 197–203.CrossRefGoogle Scholar
  6. 6.
    Zijlstra F, De Boer MJ, Hoorntje JC, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993 Mar 11; 328(10): 680–4.PubMedCrossRefGoogle Scholar
  7. 7.
    O’Neill WW, Weintraub R, Grines CL, et al. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation 1992 Dec; 86(6): 1710–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Widimsky P, Groch L, Zelizko M, et al. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory: the Prague study. Eur Heart J 2000 May; 21(10): 823–31.PubMedCrossRefGoogle Scholar
  9. 9.
    Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987 Sep 3; 317(10): 581–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Ross AM, Coyne KS, Reiner JS, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators: Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol 1999 Dec; 34(7): 1954–62.PubMedCrossRefGoogle Scholar
  11. 11.
    Polonski L, Gasior M, Wasilewski J, et al. Outcomes of primary coronary angioplasty and angioplasty after initial thrombolysis in the treatment of 374 consecutive patients with acute myocardial infarction. Am Heart J 2003 May; 145(5): 855–61.PubMedCrossRefGoogle Scholar
  12. 12.
    Spinier SA, Inverso SM. Update on strategies to improve thrombolysis for acute myocardial infarction. Pharmacotherapy 2001 Jun; 21(6): 691–716.CrossRefGoogle Scholar
  13. 13.
    Inoue T, Nishiki R, Kagayama M, et al. Long-term benefits of monteplase before coronary angioplasty in acute myocardial infarction. Am J Cardiol 2005 Feb 15; 95(4): 506–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Inoue T, Nishiki R, Kageyama M, et al. Therapeutic potential of monteplase in acute myocardial infarction as a powerful thrombolytic agent for pretreatment of coronary intervention. Cardiovasc Drug Rev 2004; 22(4): 320–33.PubMedCrossRefGoogle Scholar
  15. 15.
    Ohnishi A, Takazawa K, Fujita M, et al. Phase I study of the modified tissue plasminogen activator E6010 [in Japanese]. Jpn J Clin Pharmacol Ther 1994 Sep; 25(3): 551–62.CrossRefGoogle Scholar
  16. 16.
    Suzuki S, Saito M, Suzuki N, et al. Thrombolytic properties of novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi. J Cardiovasc Pharmacol 1991 May; 17(5): 738–46.PubMedCrossRefGoogle Scholar
  17. 17.
    Kawai C, Hosoda S, Kimata S, et al. Coronary thrombolysis in acute myocardial infarction of E6010 (novel modified t-PA): a multicenter, double-blind dose-finding study [in Japanese]. Jpn Pharmacol Ther 1994 Sep; 22(9): 3925–50.Google Scholar
  18. 18.
    Kawai C, Yui Y, Hosoda S, et al. A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: comparison with native t-PA. E6010 Study Group. J Am Coll Cardiol 1997 Jun; 29(7): 1447–53.PubMedCrossRefGoogle Scholar
  19. 19.
    Kimura K, Tsukahara K, Usui T, et al. Low-dose tissue plasminogen activator followed by planned rescue angioplasty reduces time to reperfusion for acute myocardial infarction treated at community hospitals. Jpn Circ J 2001 Oct; 65(10): 901–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Uto K, Ota Y, Mizuno M, et al. Impact of intravenous thrombolysis prior to percutaneous coronary intervention in reperfusion therapy for acute myocardial infarction [in Japanese]. J Cardiol 2002 Dec; 40(6): 241–8.PubMedGoogle Scholar
  21. 21.
    Inoue T, Sakuma M, Yaguchi I, et al. Early recanalization and plasma brain natriuretic peptide as an indicator of left ventricular function after acute myocardial infarction. Am Heart J 2002 May; 143(5): 790–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Barbash GI, Hod H, Roth A, et al. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1989 Dec 1; 64(19): 1231–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Sane DC, Stump DC, Topol EJ, et al. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. Thromb Haemost 1991 Mar 4; 65(3): 275–9.PubMedGoogle Scholar
  24. 24.
    Genser N, Lechleitner P, Maier J, et al. Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used. Clin Chem 1998 Feb; 44(2): 209–14.PubMedGoogle Scholar
  25. 25.
    Hamsten A, Wiman B, De Faire U, et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985 Dec 19; 313(25): 1557–63.PubMedCrossRefGoogle Scholar
  26. 26.
    Fujii S, Abendschein DR, Sobel BE. Augmentation of plasminogen activator inhibitor type 1 activity in plasma by thrombosis and by thrombolysis. J Am Coll Cardiol 1991 Nov 15; 18(6): 1547–54.PubMedCrossRefGoogle Scholar
  27. 27.
    Munkvad S, Gram J, Jesperson J. Increased of tissue-type plasminogen activator inhibitor type-1 (PAI-1) in plasma after thrombolytic therapy of patients with myocardial infarction: a randomized, placebo-controlled study. Fibrinolysis 1992; 6: 45–50.Google Scholar
  28. 28.
    Juhan-Vague I, Alessi MC, Joly P, et al. Plasma plasminogen activator inhibitor-1 in angina pectoris: influence of plasma insulin and acute-phase response. Arteriosclerosis 1989 May–Jun; 9(3): 362–7.PubMedCrossRefGoogle Scholar
  29. 29.
    van Meijer M, Smilde A, Tans G, et al. The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin. Blood 1997 Sep 1; 90(5): 1874–82.PubMedGoogle Scholar
  30. 30.
    Collen D, Stassen JM, Yasuda T, et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 1994 Jul; 72(1): 98–104.PubMedGoogle Scholar
  31. 31.
    Ogata N, Ogawa H, Ogata Y, et al. Comparison of thrombolytic therapies with mutant tPA (lanoteplase/SUN9216) and recombinant tPA (alteplase) for acute myocardial infarction. Jpn Circ J 1998 Nov; 62(11): 801–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Inoue T, Yaguchi I, Takayanagi K, et al. A new thrombolytic agent, monteplase, is independent of the plasminogen activator inhibitor in patients with acute myocardial infarction: initial results of the Combining Monteplase with Angioplasty (COMA) trial. Am Heart J. Epub 2002 Oct; 144(4): E5.Google Scholar
  33. 33.
    Ono T, Ogura M, Furusaki F, et al. The ratio of plasmin-α2-plasmin inhibitor complex to plasminogen activator inhibitor-1 reflects the fibrinolytic potential in plasma. Fibrinolysis Proteol 2000; 14 Suppl. 1: 72.Google Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Teruo Inoue
    • 1
  • Ryoichi Nishiki
    • 2
  • Manabu Kageyama
    • 3
  • Koichi Node
    • 1
  1. 1.Department of Cardiovascular and Renal MedicineSaga University Faculty of MedicineSagaJapan
  2. 2.Pharmaceuticals DepartmentEisai Co. LtdTokyoJapan
  3. 3.Product Planning DivisionEisai Co. LtdTokyoJapan

Personalised recommendations